Efficacy and safety of mirabegron (beta-3 adrenergic agonist) in 192 pediatric patients with neurogenic bladder or non-neurogenic lower urinary tract dysfunction (LUTD), used as monotherapy or concurrent therapy, at a single center from 2018–2024 with median follow-up of 12 months.
65% of patients (n=124) achieved partial improvement or greater, with a median time-to-improvement of 7 months. Side effects occurred in 13% (n=25), including headache (4%), nausea (4%), and hypertension (2%). No patient factors—age, sex, indication, behavioral comorbidities, or concurrent medications—predicted symptom improvement.
Single-center, retrospective observational design limits generalizability. Symptom assessment relied on clinical documentation rather than validated questionnaires or urodynamic outcomes. No control group for comparison.
Mirabegron appears safe and effective for pediatric LUTD, with a 65% improvement rate and a modest 13% side-effect rate. Consider it as monotherapy or add-on to anticholinergics in children with neurogenic or non-neurogenic bladder dysfunction, and counsel families that improvement may take up to 7 months.
Explore related topics